Stock 6855 ASCENTAGE PHARMA GROUP INTERNATIONAL
Add to a list
To use this feature you must be a member
Log inSign up

Ascentage Pharma Group International Share Price

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:20 26/04/2024 pm IST 		5-day change 1st Jan Change
17.62 HKD +1.85% Intraday chart for Ascentage Pharma Group International +12.23% -35.46%
25/04 Ascentage Pharma to Present Four Studies at US Oncology Meet MT
09/04 Ascentage Pharma Chairman Boosts Stake in Firm MT

Financials

Sales 2024 * 300M 41.39M 324M 3.45B Sales 2025 * 528M 72.93M 571M 6.08B Capitalization 4.64B 641M 5.01B 53.41B
Net income 2024 * -809M -112M -874M -9.31B Net income 2025 * -620M -85.57M -670M -7.13B EV / Sales 2024 * 15.5 x
Net cash position 2024 * - 0 0 0 Net cash position 2025 * - 0 0 0 EV / Sales 2025 * 8.78 x
P/E ratio 2024 *
-5.69 x
P/E ratio 2025 *
-7.5 x
Employees 583
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.36%
More Fundamentals * Assessed data

Chart Ascentage Pharma Group International

Dynamic Chart

Latest news about Ascentage Pharma Group International

Ascentage Pharma to Present Four Studies at US Oncology Meet MT
Ascentage Pharma Chairman Boosts Stake in Firm MT
Ascentage Pharma Group Directors Acquire Company Shares MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023 MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet MT
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting CI
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3% MT
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia CI
Ascentage Pharma Trustee Buys 100,000 Shares MT
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment MT
More news

Analyst Recommendations on Ascentage Pharma Group International

Ascentage Pharma Chairman Boosts Stake in Firm MT
Ascentage Pharma Group Directors Acquire Company Shares MT
More recommendations

Press releases Ascentage Pharma Group International

Ascentage Pharma Announces 2023 Annual Results AQ
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA PR
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference PR
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR AQ
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib AQ
More press releases

Quotes and Performance

1 day+1.85%
1 week+12.23%
Current month-0.79%
1 month-19.73%
3 months-26.89%
6 months-20.27%
Current year-35.46%
More quotes

Highs and lows

1 week
15.70
Extreme 15.7
17.80
1 month
15.42
Extreme 15.42
20.70
Current year
15.42
Extreme 15.42
28.00
1 year
15.42
Extreme 15.42
28.15
3 years
11.16
Extreme 11.16
58.20
5 years
11.16
Extreme 11.16
58.20
10 years
11.16
Extreme 11.16
58.20
More quotes

Managers and Directors - Ascentage Pharma Group International

Managers TitleAgeSince
Da Jan Yang CEO
 Chief Executive Officer 61 01/09/01
Ming Guo FOU
 Founder 67 01/09/01
Yi Qing Chen DFI
 Director of Finance/CFO 40 29/21/29
Members of the board TitleAgeSince
David Sidransky BRD
 Director/Board Member 64 31/21/31
Shao Meng Wang BRD
 Director/Board Member 60 17/17/17
Zheng Yin BRD
 Director/Board Member 52 13/19/13
More insiders

ETFs positioned on Ascentage Pharma Group International

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.84% 4 M€ -27.92%
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.01% 117 M€ +1.11% -
More ETFs positioned on Ascentage Pharma Group International

Quotes

Date Price Change Volume
26/24/26 17.62 +1.85% 615,100
25/24/25 17.3 +0.46% 990,323
24/24/24 17.22 +2.50% 873,700
23/24/23 16.8 +1.33% 1,090,984
22/24/22 16.58 +5.61% 989,800

Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST

More quotes

Company Profile

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
Sector
Biotechnology & Medical Research
Calendar
01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract Number : 3124
More about the company

Income Statement Evolution

More financial data

Ratings for Ascentage Pharma Group International

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.31 CNY
Average target price
27.24 CNY
Spread / Average Target
+67.01%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENTAGE PHARMA GROUP INTERNATIONAL Stock Ascentage Pharma Group International
-35.46% 641M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6855 Stock